200 related articles for article (PubMed ID: 28939770)
1. Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice.
Kim S; Yang X; Li Q; Wu M; Costyn L; Beharry Z; Bartlett MG; Cai H
J Biol Chem; 2017 Nov; 292(45):18422-18433. PubMed ID: 28939770
[TBL] [Abstract][Full Text] [Related]
2. Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression.
Kim S; Alsaidan OA; Goodwin O; Li Q; Sulejmani E; Han Z; Bai A; Albers T; Beharry Z; Zheng YG; Norris JS; Szulc ZM; Bielawska A; Lebedyeva I; Pegan SD; Cai H
Cancer Res; 2017 Dec; 77(24):6950-6962. PubMed ID: 29038344
[TBL] [Abstract][Full Text] [Related]
3. Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
Kim S; Yang X; Yin A; Zha J; Beharry Z; Bai A; Bielawska A; Bartlett MG; Yin H; Cai H
Prostate; 2019 Jun; 79(8):896-908. PubMed ID: 30900312
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
5. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
6. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
9. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Cai H; Babic I; Wei X; Huang J; Witte ON
Cancer Res; 2011 Feb; 71(3):862-72. PubMed ID: 21135112
[TBL] [Abstract][Full Text] [Related]
10. Rapid plasma membrane anchoring of newly synthesized p59fyn: selective requirement for NH2-terminal myristoylation and palmitoylation at cysteine-3.
van't Hof W; Resh MD
J Cell Biol; 1997 Mar; 136(5):1023-35. PubMed ID: 9060467
[TBL] [Abstract][Full Text] [Related]
11. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
12. Src controls castration recurrence of CWR22 prostate cancer xenografts.
Su B; Gillard B; Gao L; Eng KH; Gelman IH
Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.
Al-Hashimi AA; Lebeau P; Majeed F; Polena E; Lhotak Š; Collins CAF; Pinthus JH; Gonzalez-Gronow M; Hoogenes J; Pizzo SV; Crowther M; Kapoor A; Rak J; Gyulay G; D'Angelo S; Marchiò S; Pasqualini R; Arap W; Shayegan B; Austin RC
J Biol Chem; 2017 Dec; 292(51):21180-21192. PubMed ID: 29066620
[TBL] [Abstract][Full Text] [Related]
14. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-dependent degradation of active Src.
Hakak Y; Martin GS
Curr Biol; 1999 Sep; 9(18):1039-42. PubMed ID: 10508617
[TBL] [Abstract][Full Text] [Related]
17. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
[TBL] [Abstract][Full Text] [Related]
18. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
19. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
